Partner Clint Wilkins authored an article in Law360 discussing the recent Federal Circuit decision on Sanofi-Aventis Deutschland GmbH v. Mylan Pharmaceuticals Inc. and the trends around other cases involving analogous art.
Read an excerpt below:
The recent Sanofi-Aventis Deutschland GmbH v. Mylan Pharmaceuticals Inc. decision reminds petitioners in inter partes reviews of the importance of sufficiently addressing a long-standing threshold issue that seems to have been recently rediscovered: whether a reference constitutes analogous art compared with the challenged patent and therefore qualifies as prior art.
To read the full article on Law360, click here.
